We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Biomarkers of Oral Cancer Discovered

By LabMedica International staff writers
Posted on 30 Apr 2019
Epigenetics, the non-genetic influences on gene expression, is a powerful mechanism capable of altering gene expression in cancer cells without changes to the DNA sequence, and can cause tumor progression.

Oral cancer is known for its high mortality rate in developing countries, but an international team of scientists hope its latest discovery will change that. More...
The team has discovered epigenetic markers that are distinctly different in oral cancer tissues compared to the adjacent healthy tissues in patients.

Collaborating scientists from the University of Otago (Otago, New Zealand) and the Indian Statistical Institute (ISI, Kolkata, India) recruited 16 oral cancer patients in India, who were either tobacco smokers or chewers or of mixed habits, and took samples of both tumor and normal, adjacent tissue from them.

The team isolating the DNA in the samples, and discovered regions with altered epigenetic profiles in tumors cells compared to normal cells. They looked at one epigenetic mechanism, DNA methylation, which refers to the addition of methyl groups to DNA, like bookmarks. A total of 4,310 unique differentially methylated regions, mapping to 144 miRNA loci, were identified. Three distinct groups of miRNAs were differentially methylated in cancer tissues from smokers, chewers and mixed habitués. Hypermethylation of miR-503, miR-200a/b, miR-320b and miR-489 was associated with worse 5-year survival.

How these bookmarks are arranged could dictate the expression of genes and the spread of abnormal cells. Late diagnosis and poor prognosis are key problems associated with the high mortality rate of this cancer in developing countries. Of the 300,000 cases of tobacco associated oral cancer detected globally, 86% are from India. Aniruddha Chatterjee, PhD, a senior research fellow and co-author of the study, said, “This phenomenon is relatively new and under studied, particularly in oral cancer. This study is one of the first to identify epigenetic markers in oral cancer, using cutting-edge approaches.”

Roshni Roy, PhD, the lead author of the study, added, “We were also surprised to see that small molecules, called microRNA, were methylated or demethylated in the tumors from smokers or chewers or mixed habitués, suggesting that therapeutic intervention might be different in patients depending on the way the tobacco was abused.” The study was published on March 15, 2019, in the journal Epigenomics.

Related Links:
University of Otago
Indian Statistical Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Drug Testing Assays
Atellica DT 250 Analyzer
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.